1. Pomerantz LLP investigates claims against Insmed for possible securities fraud. 2. Insmed discontinued brensocatib development due to failed clinical trial results. 3. Stock price dropped 16.08% post-announcement, reflecting investor concerns.
FAQ
Why Very Bearish?
Insmed's notable stock drop following failed trial results suggests serious investor confidence loss. Historically, such clinical failures correlate with prolonged stock recovery challenges.
How important is it?
The article discusses a critical development that directly impacts Insmed's future and investor sentiments, making it highly important.
Why Short Term?
Immediate investor reactions typically drive short-term stock volatility. Long-standing impacts depend on subsequent corporate strategies and performance.
Investor Alert: Pomerantz Law Firm Investigates Claims Against Insmed Incorporated (NASDAQ: INSM)
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP has initiated an investigation on behalf of investors in Insmed Incorporated, commonly referred to as Insmed (NASDAQ: INSM). This inquiry addresses potential securities fraud or unlawful business practices by Insmed and its executive leadership. Concerned investors are encouraged to reach out to Danielle Peyton via email at newaction@pomlaw.com or by calling 646-581-9980, ext. 7980.
Details of the Investigation
The investigation focuses on whether certain officers and directors of Insmed may have engaged in misconduct that negatively impacted shareholders. This scrutiny comes on the heels of critical news regarding the Company's clinical trials.
Recent Developments Impacting Insmed’s Stock
On December 17, 2025, Insmed announced that its Phase 2b BiRCh study concerning the drug brensocatib, aimed at treating chronic rhinosinusitis without nasal polyps (CRSsNP), failed to achieve its primary and secondary efficacy endpoints. Specifically, the results from both the 10 mg and 40 mg treatment arms did not meet expectations.
Following this announcement, Insmed opted to halt the development of brensocatib. The impact of this decision was significant, with Insmed’s stock plummeting by $31.91 per share, representing a 16.08% decline, closing at $166.55 per share on December 18, 2025.
Pomerantz LLP: A Leader in Securities Class Action Lawsuits
Pomerantz LLP is recognized as a premier law firm specializing in corporate, securities, and antitrust class litigation. Founded by Abraham L. Pomerantz, the firm has a legacy of fighting for the rights of victims of securities fraud and corporate misconduct. Over its 85 years of operation, Pomerantz has successfully recovered substantial multimillion-dollar awards for affected class members.
For more information about Pomerantz and their class action services, visit www.pomlaw.com.
Next Steps for Investors
- If you are an investor in Insmed (NASDAQ: INSM), consider seeking legal advice.
- Investors can contact Pomerantz LLP to learn more about joining the class action lawsuit.
- Stay updated on further developments regarding Insmed's stock and corporate actions.
For inquiries, please contact: Danielle Peyton, Pomerantz LLP, dpeyton@pomlaw.com, 646-581-9980, ext. 7980.